Table. Overview of the literature.

Study	n	Treatment	Brain metastases	Survival (years)	Comments
Shen; 2012 (25)	1	RAI + RS + sorafenib	s	n.e.
Klubo-Gwiezdzinska; 2012 (30)	2	RAI	n.e.	n.e.
Miranda; 2010 (26)	1	RAI + OP + RTX + RS	m	10
Walczyk; 2010 (31)	1	RAI + RTX	n.e.	2	poorly differentiated hyroid carcinoma
Erem; 2004 (32)	1	OP + RTX + RAI	s	n.e.
McWilliams; 2003 (33)	4	2 OP + RAI 1 OP + RTX + RAI 1 OP + RS + RAI	s	1.5
Cha; 2000 (34)	1	OP + RAI + RTX + RS	s	> 3
Misaki; 2000 (35)	9	4 RAI + RTX 2 RAI + RS 2 OP + RAI 1 OP + RAI + RTX	5 s 4 m	0.8	no significant intracranial RAI uptake
Chiu; 1997 (11)	24 (+ 8 post mortem)	7 OP 13 RTX 6 CTX 3 RAI	11 s 12 m	1	only 3/18 patients with RAI uptake
Samuel; 1997 (18)	15	3 RAI in combination with OP, RTX and/or CTX	6 s 9 m	< 0.5
Biswal; 1994 (17)	5	2 RTX + RAI 1 RTX 1 OP + RTX + RAI 1 OP + RAI	s	2 died 4 mo and 7 yr, resp., after diagnosis; 3 are alive 12–23 mo after treatment
Miyamoto; 1991 (36)	2	RAI	n.e.	n.e.	no RAI uptake and no response to treatment
Andrews; 1987 (37)	1	OP + RTX + RAI	s	2.75
Krishnamurthy; 1977 (24)	2	RAI	n.e.	2	cerebellum

n, number of patients; s, solitary; m, multiple; n.e., not examined; RAI, radioactive iodine; OP, operation; RTX, radiotherapy; RS, gamma knife radiosurgery; CTX, chemotherapy